The discussion related to these products has changed dramatically from those had in previous years; in the past, the industry was discussing the regulatory framework and how the different regulatory agencies, from Mexico to Argentina, would regulate these new therapeutic options. Now, after the maturity of the laws and the construction of different regulatory pathways for biosimilars in most of the countries, the discussion has moved on to the different challenges that the industry, whether local or foreign, faces in commercializing biosimilars.
In most of the countries, governments are promoting the introduction of the biosimilars, due in part to the constraints they face in paying for high-cost innovative biologics, in addition to controlling healthcare spending linked with the increasing prevalence of diseases like cancer, diabetes, and other chronic conditions.
in the coming years, we will see a dynamic market with many players moving between countries with different regulatory frameworks and health system compositions, all trying to survive deep price reductions while demonstrating added value through the development of more real-world evidence or benefits in product improvements. At the same time, we will see these players increasing patient access to medicines. In the end, patients will benefit from these market dynamics with the introduction of therapeutic options that can help to overcome the access disparities that our region currently has.
Industry Executives from Latam
- Analytical science
- Regulatory compliance
- Quality Control
- Clinical immunology
- Scientific Affairs
- Business Development
Program at a Glance
How to reinforce national industry to attract foreign investment
How to improve confidence in biosimilars to attract foreign investment
Biosimilars and their Impact in Latin America's Growing Pharmaceutical Market
Due to the loss of patent exclusivity of several biological pharmaceuticals in upcoming years. Market share, development and production of vaccines
Pharmacovigilance Challenges for Biosimilars
State of affairs, how can it be improved?
The impact of single-use technologies in Biosimilars manufacturing process
Sterility within Production Processes, Proper Maintenance of the production Environment
Partnerships for Productive Development and their Contribution to Brazil’s PNI
Public initiatives that contribute to the growth of the pharmaceutical market and the improvement of Brazil’s health care system
Panel, The latest update regarding the patent approval in Brazil. Understanding the perspectives. Covid-19 vaccines patent suspension and their efects in the pharmaceutical industry. A conversation about the industry but also the bioethic component of the subject.
Upcoming Considerations for Biosimilars in Brazil
What’s the future of biosimilars after the pandemic is under control
Full programme in the PDF Agenda
The Sartorius Group is a leading international partner of life science research and the biopharmaceutical industry. With innovative laboratory instruments and consumables, the Group’s Lab Products & Services Division concentrates on serving the needs of laboratories performing research and quality control at pharma and biopharma companies and those of academic research institutes.
Thermo Fisher Scientific is the world leader in serving science, with annual revenue exceeding $25 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon.
Cytiva is a global provider of technologies and services that help advance and accelerate the development and production of therapeutic products. Promoting training, speed and efficiency for research and production workflows, allowing the delivery of innovative medicines to patients.
We develop alliances with pharmaceutical companies, using Terumo technology to develop, manufacture and supply solutions to injectable drug delivery challenges. We pride ourselves on offering a portfolio of products and services for the pharmaceutical industry. By anticipating trends and maintaining a constant dialogue, we provide a first class customer experience.
The production of biologic-based pharmaceuticals is long and complex. Rapid answers from in-process controls confirm your production process is operating as designed—efficiently confirming product quality. With the most comprehensive portfolio of microbiology solutions for bioproduction, bioMérieux helps protect your customers, keep you in compliance, and improve your bottom line.